Alcon's Robust Scientific Program Presented at BCLA 2021
Alcon Research Completes Renewal Deal at Irvine Co.'s Irvine Building
Alcon Debuts as Independent, Publicly Traded Company
Eye care device maker Alcon sees a brilliant future ahead
VIDEO
Udaariyaan: 16 August|| संधू हाउस में आसमां को मिला हरलीन का Clue, अतीत से उठा पर्दा||
Alcon Vivity IOL
Phaco: Alcon Vivity IOL
Colours look faded? Alcon cataract lenses to see your world vividly
Labcon Protect Plus + Labcon Cloro Test
2023 Huntington Middle School & Alcon Research
COMMENTS
Clinical Research Portal
Alcon conducts clinical trials worldwide to evaluate the safety and effectiveness of our products.
Alcon Announces Largest-Ever Scientific Presence at ASCRS 2023
Print. Alcon innovations featured in approximately 180 abstracts across cataract, glaucoma, refractive, visualization and ocular health1. New data demonstrates comparable range of vision and intermediate visual acuity between Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL2.
Scientific Publications
Click below to access science & technology articles on Alcon products and therapeutic areas. Learn more You are on a website for Health Care Professionals in the United States
Alcon is the global leader in eye care, dedicated to helping
The year 2022 marked Alcon’s 75th anniversary and, as we celebrated this milestone by reinforcing our commitment to delivering innovations that improve sight, we continued our important work of expanding access to eye care to communities around the world. Alcon sees a world where treatable, preventable conditions
Alcon Reports Fourth Quarter and Full Year 2021 Results
PDF Print. Fourth Quarter 2021 sales of $2.1 billion, up 11% or 13% constant currency. Full Year 2021 sales of $8.2 billion, up 22% or 20% constant currency. Above-market growth in both Surgical and Vision Care; sales momentum from key products, new product launches and commercial execution.
IMAGES
VIDEO
COMMENTS
Alcon conducts clinical trials worldwide to evaluate the safety and effectiveness of our products.
Print. Alcon innovations featured in approximately 180 abstracts across cataract, glaucoma, refractive, visualization and ocular health1. New data demonstrates comparable range of vision and intermediate visual acuity between Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL2.
Click below to access science & technology articles on Alcon products and therapeutic areas. Learn more You are on a website for Health Care Professionals in the United States
The year 2022 marked Alcon’s 75th anniversary and, as we celebrated this milestone by reinforcing our commitment to delivering innovations that improve sight, we continued our important work of expanding access to eye care to communities around the world. Alcon sees a world where treatable, preventable conditions
PDF Print. Fourth Quarter 2021 sales of $2.1 billion, up 11% or 13% constant currency. Full Year 2021 sales of $8.2 billion, up 22% or 20% constant currency. Above-market growth in both Surgical and Vision Care; sales momentum from key products, new product launches and commercial execution.